



Altimune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

March 8, 2022

GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022.

Altimune management will host a conference call at 8:30 am E.T. on March 15 to discuss financial results and provide a business update.

Conference Call Information:

Date: Tuesday, March 15
Time: 8:30 am Eastern Time
Domestic Dial-in: (844) 615-6509
International Dial-in: (918) 922-3148
Conference ID: 4557398
Webcast: <https://edge.media-server.com/mmc/p/5www3cgz>

About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

Investor and Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com



Source: Altimune, Inc